Newsroom
Press
Releases
Press Releases
- 4.27.2023
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
CAMBRIDGE, Mass. – April 27, 2023 – EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call
- 2.23.2023
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemalimab: MAAs accepted for
- 1.3.2023
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
EQRx, Inc. announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST.
- 12.19.2022
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review its marketing authorization application (MAA) for sugemalimab, an anti-programmed death-ligand 1 (PD-L1) antibody, in combination with chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).
- 12.2.2022
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
EQRx announced that the European Medicines Agency (EMA) has accepted for review its marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in development for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations, and for adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.